DQS0 Stock Overview
A clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
TNF Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.89 |
| 52 Week High | US$61.80 |
| 52 Week Low | US$1.89 |
| Beta | 2.91 |
| 11 Month Change | 0% |
| 3 Month Change | -22.22% |
| 1 Year Change | -96.14% |
| 33 Year Change | -97.72% |
| 5 Year Change | n/a |
| Change since IPO | -98.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| DQS0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.8% | 1.1% |
| 1Y | -96.1% | -16.7% | 12.5% |
Return vs Industry: DQS0 underperformed the German Pharmaceuticals industry which returned -22.6% over the past year.
Return vs Market: DQS0 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| DQS0 volatility | |
|---|---|
| DQS0 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DQS0's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine DQS0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 6 | n/a | tnfpharma.com |
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immunometabolic system and its pro-inflammatory cytokines to treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression.
TNF Pharmaceuticals, Inc. Fundamentals Summary
| DQS0 fundamental statistics | |
|---|---|
| Market cap | €5.02m |
| Earnings (TTM) | -€7.62m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs DQS0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DQS0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$8.22m |
| Earnings | -US$8.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.81 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DQS0 perform over the long term?
See historical performance and comparison